# Efficacy and Safety of Celecoxib as Add-on Therapy to Risperidone Versus Risperidone Alone in Patients With Schizophrenia

> **NCT00639483** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 270 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Celecoxib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00639483
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03
- **Primary completion:** —
- **Final completion:** 2004-01
- **Target enrollment:** 270 (ACTUAL)
- **Last updated:** 2009-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00639483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00639483, "Efficacy and Safety of Celecoxib as Add-on Therapy to Risperidone Versus Risperidone Alone in Patients With Schizophrenia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00639483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*